Supportive evidence for reduced expression of GNB1L in schizophrenia

Hiroki Ishiguro, Minori Koga, Yasue Horiuchi, Emiko Noguchi, Miyuki Morikawa, Yoshimi Suzuki, Makoto Arai, Kazuhiro Niizato, Shyuji Iritani, Masanari Itokawa, Toshiya Inada, Nakao Iwata, Norio Ozaki, Hiroshi Ujike, Hiroshi Kunugi, Tsukasa Sasaki, Makoto Takahashi, Yuichiro Watanabe, Toshiyuki Someya, Akiyoshi Kakita & 3 others Hitoshi Takahashi, Hiroyuki Nawa, Tadao Arinami

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Chromosome 22q11 deletion syndrome (22q11DS) increases the risk of development of schizophrenia more than 10 times compared with that of the general population, indicating that haploinsufficiency of a subset of the more than 20 genes contained in the 22q11DS region could increase the risk of schizophrenia. In the present study, we screened for genes located in the 22q11DS region that are expressed at lower levels in postmortem prefrontal cortex of patients with schizophrenia than in those of controls. Methods: Gene expression was screened by Illumina Human-6 Expression BeadChip arrays and confirmed by real-time reverse transcription-polymerase chain reaction assays and Western blot analysis. Results: Expression of GNB1L was lower in patients with schizophrenia than in control subjects in both Australian (10 schizophrenia cases and 10 controls) and Japanese (43 schizophrenia cases and 11 controls) brain samples. TBX1 could not be evaluated due to its low expression levels. Expression levels of the other genes were not significantly lower in patients with schizophrenia than in control subjects. Association analysis of tag single-nucleotide polymorphisms in the GNB1L gene region did not confirm excess homozygosity in 1918 Japanese schizophrenia cases and 1909 Japanese controls. Haloperidol treatment for 50 weeks increased Gnb1l gene expression in prefrontal cortex of mice. Conclusions: Taken together with the impaired prepulse inhibition observed in heterozygous Gnb1l knockout mice reported by the previous study, the present findings support assertions that GNB1L is one of the genes in the 22q11DS region responsible for increasing the risk of schizophrenia.

Original languageEnglish
Pages (from-to)756-765
Number of pages10
JournalSchizophrenia Bulletin
Volume36
Issue number4
DOIs
Publication statusPublished - 01-07-2010

Fingerprint

Schizophrenia
22q11 Deletion Syndrome
Genes
Prefrontal Cortex
Gene Expression
Haploinsufficiency
Chromosome Deletion
Haloperidol
Knockout Mice
Reverse Transcription
Single Nucleotide Polymorphism
Western Blotting
Polymerase Chain Reaction
Brain
Population

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Ishiguro, H., Koga, M., Horiuchi, Y., Noguchi, E., Morikawa, M., Suzuki, Y., ... Arinami, T. (2010). Supportive evidence for reduced expression of GNB1L in schizophrenia. Schizophrenia Bulletin, 36(4), 756-765. https://doi.org/10.1093/schbul/sbn160
Ishiguro, Hiroki ; Koga, Minori ; Horiuchi, Yasue ; Noguchi, Emiko ; Morikawa, Miyuki ; Suzuki, Yoshimi ; Arai, Makoto ; Niizato, Kazuhiro ; Iritani, Shyuji ; Itokawa, Masanari ; Inada, Toshiya ; Iwata, Nakao ; Ozaki, Norio ; Ujike, Hiroshi ; Kunugi, Hiroshi ; Sasaki, Tsukasa ; Takahashi, Makoto ; Watanabe, Yuichiro ; Someya, Toshiyuki ; Kakita, Akiyoshi ; Takahashi, Hitoshi ; Nawa, Hiroyuki ; Arinami, Tadao. / Supportive evidence for reduced expression of GNB1L in schizophrenia. In: Schizophrenia Bulletin. 2010 ; Vol. 36, No. 4. pp. 756-765.
@article{0ae581ede8c5481cbe171a0c1c546251,
title = "Supportive evidence for reduced expression of GNB1L in schizophrenia",
abstract = "Background: Chromosome 22q11 deletion syndrome (22q11DS) increases the risk of development of schizophrenia more than 10 times compared with that of the general population, indicating that haploinsufficiency of a subset of the more than 20 genes contained in the 22q11DS region could increase the risk of schizophrenia. In the present study, we screened for genes located in the 22q11DS region that are expressed at lower levels in postmortem prefrontal cortex of patients with schizophrenia than in those of controls. Methods: Gene expression was screened by Illumina Human-6 Expression BeadChip arrays and confirmed by real-time reverse transcription-polymerase chain reaction assays and Western blot analysis. Results: Expression of GNB1L was lower in patients with schizophrenia than in control subjects in both Australian (10 schizophrenia cases and 10 controls) and Japanese (43 schizophrenia cases and 11 controls) brain samples. TBX1 could not be evaluated due to its low expression levels. Expression levels of the other genes were not significantly lower in patients with schizophrenia than in control subjects. Association analysis of tag single-nucleotide polymorphisms in the GNB1L gene region did not confirm excess homozygosity in 1918 Japanese schizophrenia cases and 1909 Japanese controls. Haloperidol treatment for 50 weeks increased Gnb1l gene expression in prefrontal cortex of mice. Conclusions: Taken together with the impaired prepulse inhibition observed in heterozygous Gnb1l knockout mice reported by the previous study, the present findings support assertions that GNB1L is one of the genes in the 22q11DS region responsible for increasing the risk of schizophrenia.",
author = "Hiroki Ishiguro and Minori Koga and Yasue Horiuchi and Emiko Noguchi and Miyuki Morikawa and Yoshimi Suzuki and Makoto Arai and Kazuhiro Niizato and Shyuji Iritani and Masanari Itokawa and Toshiya Inada and Nakao Iwata and Norio Ozaki and Hiroshi Ujike and Hiroshi Kunugi and Tsukasa Sasaki and Makoto Takahashi and Yuichiro Watanabe and Toshiyuki Someya and Akiyoshi Kakita and Hitoshi Takahashi and Hiroyuki Nawa and Tadao Arinami",
year = "2010",
month = "7",
day = "1",
doi = "10.1093/schbul/sbn160",
language = "English",
volume = "36",
pages = "756--765",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "4",

}

Ishiguro, H, Koga, M, Horiuchi, Y, Noguchi, E, Morikawa, M, Suzuki, Y, Arai, M, Niizato, K, Iritani, S, Itokawa, M, Inada, T, Iwata, N, Ozaki, N, Ujike, H, Kunugi, H, Sasaki, T, Takahashi, M, Watanabe, Y, Someya, T, Kakita, A, Takahashi, H, Nawa, H & Arinami, T 2010, 'Supportive evidence for reduced expression of GNB1L in schizophrenia', Schizophrenia Bulletin, vol. 36, no. 4, pp. 756-765. https://doi.org/10.1093/schbul/sbn160

Supportive evidence for reduced expression of GNB1L in schizophrenia. / Ishiguro, Hiroki; Koga, Minori; Horiuchi, Yasue; Noguchi, Emiko; Morikawa, Miyuki; Suzuki, Yoshimi; Arai, Makoto; Niizato, Kazuhiro; Iritani, Shyuji; Itokawa, Masanari; Inada, Toshiya; Iwata, Nakao; Ozaki, Norio; Ujike, Hiroshi; Kunugi, Hiroshi; Sasaki, Tsukasa; Takahashi, Makoto; Watanabe, Yuichiro; Someya, Toshiyuki; Kakita, Akiyoshi; Takahashi, Hitoshi; Nawa, Hiroyuki; Arinami, Tadao.

In: Schizophrenia Bulletin, Vol. 36, No. 4, 01.07.2010, p. 756-765.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Supportive evidence for reduced expression of GNB1L in schizophrenia

AU - Ishiguro, Hiroki

AU - Koga, Minori

AU - Horiuchi, Yasue

AU - Noguchi, Emiko

AU - Morikawa, Miyuki

AU - Suzuki, Yoshimi

AU - Arai, Makoto

AU - Niizato, Kazuhiro

AU - Iritani, Shyuji

AU - Itokawa, Masanari

AU - Inada, Toshiya

AU - Iwata, Nakao

AU - Ozaki, Norio

AU - Ujike, Hiroshi

AU - Kunugi, Hiroshi

AU - Sasaki, Tsukasa

AU - Takahashi, Makoto

AU - Watanabe, Yuichiro

AU - Someya, Toshiyuki

AU - Kakita, Akiyoshi

AU - Takahashi, Hitoshi

AU - Nawa, Hiroyuki

AU - Arinami, Tadao

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Background: Chromosome 22q11 deletion syndrome (22q11DS) increases the risk of development of schizophrenia more than 10 times compared with that of the general population, indicating that haploinsufficiency of a subset of the more than 20 genes contained in the 22q11DS region could increase the risk of schizophrenia. In the present study, we screened for genes located in the 22q11DS region that are expressed at lower levels in postmortem prefrontal cortex of patients with schizophrenia than in those of controls. Methods: Gene expression was screened by Illumina Human-6 Expression BeadChip arrays and confirmed by real-time reverse transcription-polymerase chain reaction assays and Western blot analysis. Results: Expression of GNB1L was lower in patients with schizophrenia than in control subjects in both Australian (10 schizophrenia cases and 10 controls) and Japanese (43 schizophrenia cases and 11 controls) brain samples. TBX1 could not be evaluated due to its low expression levels. Expression levels of the other genes were not significantly lower in patients with schizophrenia than in control subjects. Association analysis of tag single-nucleotide polymorphisms in the GNB1L gene region did not confirm excess homozygosity in 1918 Japanese schizophrenia cases and 1909 Japanese controls. Haloperidol treatment for 50 weeks increased Gnb1l gene expression in prefrontal cortex of mice. Conclusions: Taken together with the impaired prepulse inhibition observed in heterozygous Gnb1l knockout mice reported by the previous study, the present findings support assertions that GNB1L is one of the genes in the 22q11DS region responsible for increasing the risk of schizophrenia.

AB - Background: Chromosome 22q11 deletion syndrome (22q11DS) increases the risk of development of schizophrenia more than 10 times compared with that of the general population, indicating that haploinsufficiency of a subset of the more than 20 genes contained in the 22q11DS region could increase the risk of schizophrenia. In the present study, we screened for genes located in the 22q11DS region that are expressed at lower levels in postmortem prefrontal cortex of patients with schizophrenia than in those of controls. Methods: Gene expression was screened by Illumina Human-6 Expression BeadChip arrays and confirmed by real-time reverse transcription-polymerase chain reaction assays and Western blot analysis. Results: Expression of GNB1L was lower in patients with schizophrenia than in control subjects in both Australian (10 schizophrenia cases and 10 controls) and Japanese (43 schizophrenia cases and 11 controls) brain samples. TBX1 could not be evaluated due to its low expression levels. Expression levels of the other genes were not significantly lower in patients with schizophrenia than in control subjects. Association analysis of tag single-nucleotide polymorphisms in the GNB1L gene region did not confirm excess homozygosity in 1918 Japanese schizophrenia cases and 1909 Japanese controls. Haloperidol treatment for 50 weeks increased Gnb1l gene expression in prefrontal cortex of mice. Conclusions: Taken together with the impaired prepulse inhibition observed in heterozygous Gnb1l knockout mice reported by the previous study, the present findings support assertions that GNB1L is one of the genes in the 22q11DS region responsible for increasing the risk of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=77958180925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958180925&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbn160

DO - 10.1093/schbul/sbn160

M3 - Article

VL - 36

SP - 756

EP - 765

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 4

ER -

Ishiguro H, Koga M, Horiuchi Y, Noguchi E, Morikawa M, Suzuki Y et al. Supportive evidence for reduced expression of GNB1L in schizophrenia. Schizophrenia Bulletin. 2010 Jul 1;36(4):756-765. https://doi.org/10.1093/schbul/sbn160